Cargando…

Is it the Right Time to Introduce the Hepatitis B Booster Vaccine in National Immunization Schedule? An Analysis from the Available Evidence

Hepatitis B virus (HBV) infection is a global health concern, and it is considered one of the deadliest infections in the world, having nearly 1.2 million deaths annually. Around 75% of all global HBV carriers live in the Asia-Pacific region. In this regard, India has a prevalence ranging between 2%...

Descripción completa

Detalles Bibliográficos
Autores principales: Bhattacharya, Sudip, Gökdemir, Özden, Bashar, Md Abu, Thiyagarajan, Arulmani, Singh, Amarjeet
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Wolters Kluwer - Medknow 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8117886/
https://www.ncbi.nlm.nih.gov/pubmed/34035566
http://dx.doi.org/10.4103/ijcm.IJCM_439_19
_version_ 1783691651039887360
author Bhattacharya, Sudip
Gökdemir, Özden
Bashar, Md Abu
Thiyagarajan, Arulmani
Singh, Amarjeet
author_facet Bhattacharya, Sudip
Gökdemir, Özden
Bashar, Md Abu
Thiyagarajan, Arulmani
Singh, Amarjeet
author_sort Bhattacharya, Sudip
collection PubMed
description Hepatitis B virus (HBV) infection is a global health concern, and it is considered one of the deadliest infections in the world, having nearly 1.2 million deaths annually. Around 75% of all global HBV carriers live in the Asia-Pacific region. In this regard, India has a prevalence ranging between 2% and 7% with exposure rates of 10%–60%. Hepatitis B is a vaccine-preventable disease. In India, the World Health Organization protocol for hepatitis B vaccination has been followed, and it is given free of cost in public health facilities under the National Immunization Schedule. Despite the free hepatitis vaccination program in India, coverage and awareness are low. Low awareness, followed by low coverage of hepatitis vaccination, can prove dangerous for the Indian population in the long run. A majority of chronic hepatitis cases progress silently to end-stage liver disease without having many signs and symptoms. Once occurred, a complete cure is not possible with currently available drugs. The studies from neighboring countries such as China and Taiwan documented that the impact of single-dose booster for children of 10 years has made a significant difference from the cost-effectiveness perspective. They have also included the booster dose in their national vaccination program. Considering the low level of vaccination awareness, small coverage, high disease burden, and high treatment cost, now, it is high time for India to introduce hepatitis B booster vaccine.
format Online
Article
Text
id pubmed-8117886
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher Wolters Kluwer - Medknow
record_format MEDLINE/PubMed
spelling pubmed-81178862021-05-24 Is it the Right Time to Introduce the Hepatitis B Booster Vaccine in National Immunization Schedule? An Analysis from the Available Evidence Bhattacharya, Sudip Gökdemir, Özden Bashar, Md Abu Thiyagarajan, Arulmani Singh, Amarjeet Indian J Community Med View Point Hepatitis B virus (HBV) infection is a global health concern, and it is considered one of the deadliest infections in the world, having nearly 1.2 million deaths annually. Around 75% of all global HBV carriers live in the Asia-Pacific region. In this regard, India has a prevalence ranging between 2% and 7% with exposure rates of 10%–60%. Hepatitis B is a vaccine-preventable disease. In India, the World Health Organization protocol for hepatitis B vaccination has been followed, and it is given free of cost in public health facilities under the National Immunization Schedule. Despite the free hepatitis vaccination program in India, coverage and awareness are low. Low awareness, followed by low coverage of hepatitis vaccination, can prove dangerous for the Indian population in the long run. A majority of chronic hepatitis cases progress silently to end-stage liver disease without having many signs and symptoms. Once occurred, a complete cure is not possible with currently available drugs. The studies from neighboring countries such as China and Taiwan documented that the impact of single-dose booster for children of 10 years has made a significant difference from the cost-effectiveness perspective. They have also included the booster dose in their national vaccination program. Considering the low level of vaccination awareness, small coverage, high disease burden, and high treatment cost, now, it is high time for India to introduce hepatitis B booster vaccine. Wolters Kluwer - Medknow 2021 2021-03-01 /pmc/articles/PMC8117886/ /pubmed/34035566 http://dx.doi.org/10.4103/ijcm.IJCM_439_19 Text en Copyright: © 2021 Indian Journal of Community Medicine https://creativecommons.org/licenses/by-nc-sa/4.0/This is an open access journal, and articles are distributed under the terms of the Creative Commons Attribution-NonCommercial-ShareAlike 4.0 License, which allows others to remix, tweak, and build upon the work non-commercially, as long as appropriate credit is given and the new creations are licensed under the identical terms.
spellingShingle View Point
Bhattacharya, Sudip
Gökdemir, Özden
Bashar, Md Abu
Thiyagarajan, Arulmani
Singh, Amarjeet
Is it the Right Time to Introduce the Hepatitis B Booster Vaccine in National Immunization Schedule? An Analysis from the Available Evidence
title Is it the Right Time to Introduce the Hepatitis B Booster Vaccine in National Immunization Schedule? An Analysis from the Available Evidence
title_full Is it the Right Time to Introduce the Hepatitis B Booster Vaccine in National Immunization Schedule? An Analysis from the Available Evidence
title_fullStr Is it the Right Time to Introduce the Hepatitis B Booster Vaccine in National Immunization Schedule? An Analysis from the Available Evidence
title_full_unstemmed Is it the Right Time to Introduce the Hepatitis B Booster Vaccine in National Immunization Schedule? An Analysis from the Available Evidence
title_short Is it the Right Time to Introduce the Hepatitis B Booster Vaccine in National Immunization Schedule? An Analysis from the Available Evidence
title_sort is it the right time to introduce the hepatitis b booster vaccine in national immunization schedule? an analysis from the available evidence
topic View Point
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8117886/
https://www.ncbi.nlm.nih.gov/pubmed/34035566
http://dx.doi.org/10.4103/ijcm.IJCM_439_19
work_keys_str_mv AT bhattacharyasudip isittherighttimetointroducethehepatitisbboostervaccineinnationalimmunizationscheduleananalysisfromtheavailableevidence
AT gokdemirozden isittherighttimetointroducethehepatitisbboostervaccineinnationalimmunizationscheduleananalysisfromtheavailableevidence
AT basharmdabu isittherighttimetointroducethehepatitisbboostervaccineinnationalimmunizationscheduleananalysisfromtheavailableevidence
AT thiyagarajanarulmani isittherighttimetointroducethehepatitisbboostervaccineinnationalimmunizationscheduleananalysisfromtheavailableevidence
AT singhamarjeet isittherighttimetointroducethehepatitisbboostervaccineinnationalimmunizationscheduleananalysisfromtheavailableevidence